The financial implications of investigating false-positive and true-positive mammograms in a national breast cancer screening program.

IF 1.4 4区 医学 Q3 HEALTH CARE SCIENCES & SERVICES
Jason Soon, Nehmat Houssami, Michelle Clemson, Darren Lockie, Rachel Farber, Alexandra Barratt, Adam Elshaug, Kirsten Howard
{"title":"The financial implications of investigating false-positive and true-positive mammograms in a national breast cancer screening program.","authors":"Jason Soon,&nbsp;Nehmat Houssami,&nbsp;Michelle Clemson,&nbsp;Darren Lockie,&nbsp;Rachel Farber,&nbsp;Alexandra Barratt,&nbsp;Adam Elshaug,&nbsp;Kirsten Howard","doi":"10.1071/AH22120","DOIUrl":null,"url":null,"abstract":"<p><p>Objectives To determine the total annual screening and further-investigation costs of investigating false-positive and true-positive mammograms in the Australian population breast-screening program. Methods This economic analysis used aggregate-level retrospective cohort data of women screened at a breast-screening clinic. Counts and frequencies of each diagnostic workup-sequence recorded were scaled up to national figures and costed by estimating per-patient costs of procedures using screening clinic cost data. Main outcomes and measures estimated were percentage share of total annual screening and further-investigation costs for the Australian population breast-screening program of investigating false-positive and true-positive mammograms. Secondary outcomes determined were average costs of investigating each false-positive and true-positive mammogram. Sensitivity analyses involved recalculating results excluding subgroups of patients below and above the screening age range of 50-74 years. Results Of 8235 patients, the median age was 60.35 years with interquartile range of 54.17-67.17 years. A total of 15.4% (ranging from 13.4 to 15.4% under different scenarios) of total annual screening and further-investigation costs were from investigating false-positive mammograms. This exceeded the share of costs from investigating true-positives (13%). Conclusions We have developed a transparent and non-onerous approach for estimating the costs of false-positive and true-positive mammograms associated with the national breast-screening program. While determining an optimal balance between false-positives and true-positive rates must rely primarily on health outcomes, costs are an important consideration. We recommend that future research adopts and refines similar approaches to facilitate better monitoring of these costs, benchmark against estimates from other screening programs, and support optimal policy development.</p>","PeriodicalId":55425,"journal":{"name":"Australian Health Review","volume":null,"pages":null},"PeriodicalIF":1.4000,"publicationDate":"2023-04-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":"0","resultStr":null,"platform":"Semanticscholar","paperid":null,"PeriodicalName":"Australian Health Review","FirstCategoryId":"3","ListUrlMain":"https://doi.org/10.1071/AH22120","RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":null,"EPubDate":"","PubModel":"","JCR":"Q3","JCRName":"HEALTH CARE SCIENCES & SERVICES","Score":null,"Total":0}
引用次数: 0

Abstract

Objectives To determine the total annual screening and further-investigation costs of investigating false-positive and true-positive mammograms in the Australian population breast-screening program. Methods This economic analysis used aggregate-level retrospective cohort data of women screened at a breast-screening clinic. Counts and frequencies of each diagnostic workup-sequence recorded were scaled up to national figures and costed by estimating per-patient costs of procedures using screening clinic cost data. Main outcomes and measures estimated were percentage share of total annual screening and further-investigation costs for the Australian population breast-screening program of investigating false-positive and true-positive mammograms. Secondary outcomes determined were average costs of investigating each false-positive and true-positive mammogram. Sensitivity analyses involved recalculating results excluding subgroups of patients below and above the screening age range of 50-74 years. Results Of 8235 patients, the median age was 60.35 years with interquartile range of 54.17-67.17 years. A total of 15.4% (ranging from 13.4 to 15.4% under different scenarios) of total annual screening and further-investigation costs were from investigating false-positive mammograms. This exceeded the share of costs from investigating true-positives (13%). Conclusions We have developed a transparent and non-onerous approach for estimating the costs of false-positive and true-positive mammograms associated with the national breast-screening program. While determining an optimal balance between false-positives and true-positive rates must rely primarily on health outcomes, costs are an important consideration. We recommend that future research adopts and refines similar approaches to facilitate better monitoring of these costs, benchmark against estimates from other screening programs, and support optimal policy development.

在国家乳腺癌筛查项目中调查假阳性和真阳性乳房x光检查的经济意义。
目的确定澳大利亚人群乳腺筛查项目中每年筛查和进一步调查假阳性和真阳性乳房x线照片的总费用。方法本经济分析采用在乳腺筛查诊所接受筛查的妇女的总水平回顾性队列数据。记录的每个诊断工作序列的计数和频率按比例放大到国家数据,并通过使用筛查诊所成本数据估计每个患者的程序成本来进行成本计算。估计的主要结果和措施是澳大利亚人口乳腺筛查项目调查假阳性和真阳性乳房x光检查的年度筛查和进一步调查费用的百分比。确定的次要结果是调查每个假阳性和真阳性乳房x光片的平均费用。敏感性分析包括重新计算结果,排除低于和高于50-74岁筛查年龄范围的患者亚组。结果8235例患者中位年龄为60.35岁,四分位数范围为54.17 ~ 67.17岁。每年筛查和进一步调查费用总额的15.4%(不同情况下为13.4%至15.4%)来自检查假阳性乳房x线照片。这超过了调查真阳性的成本份额(13%)。结论:我们已经开发了一种透明且不繁琐的方法来估算与国家乳房筛查计划相关的假阳性和真阳性乳房x光检查的成本。虽然确定假阳性和真阳性率之间的最佳平衡必须主要依靠健康结果,但成本是一个重要的考虑因素。我们建议未来的研究采用并改进类似的方法,以便更好地监测这些成本,以其他筛查项目的估算为基准,并支持最优政策的制定。
本文章由计算机程序翻译,如有差异,请以英文原文为准。
求助全文
约1分钟内获得全文 求助全文
来源期刊
Australian Health Review
Australian Health Review 医学-卫生保健
CiteScore
2.90
自引率
5.60%
发文量
134
审稿时长
6-12 weeks
期刊介绍: Australian Health Review is an international, peer-reviewed journal that publishes contributions on all aspects of health policy, management and governance; healthcare delivery systems; workforce; health financing; and other matters of interest to those working in health care. In addition to analyses and commentary, the journal publishes original research from practitioners – managers and clinicians – and reports of breakthrough projects that demonstrate better ways of delivering care. Australian Health Review explores major national and international health issues and questions, enabling health professionals to keep their fingers on the pulse of the nation’s health decisions and to know what the most influential commentators and decision makers are thinking. Australian Health Review is a valuable resource for managers, policy makers and clinical staff in health organisations, including government departments, hospitals, community centres and aged-care facilities, as well as anyone with an interest in the health industry. Australian Health Review is published by CSIRO Publishing on behalf of the Australian Healthcare and Hospitals Association.
×
引用
GB/T 7714-2015
复制
MLA
复制
APA
复制
导出至
BibTeX EndNote RefMan NoteFirst NoteExpress
×
提示
您的信息不完整,为了账户安全,请先补充。
现在去补充
×
提示
您因"违规操作"
具体请查看互助需知
我知道了
×
提示
确定
请完成安全验证×
copy
已复制链接
快去分享给好友吧!
我知道了
右上角分享
点击右上角分享
0
联系我们:info@booksci.cn Book学术提供免费学术资源搜索服务,方便国内外学者检索中英文文献。致力于提供最便捷和优质的服务体验。 Copyright © 2023 布克学术 All rights reserved.
京ICP备2023020795号-1
ghs 京公网安备 11010802042870号
Book学术文献互助
Book学术文献互助群
群 号:481959085
Book学术官方微信